The act, which passed last year, gives Medicare the power to negotiate drug prices with manufacturers for the first time in nearly 60 years. The agreed-upon prices for the first round of drugs are scheduled to go into effect in 2026.
The act has not gone without controversy, with drugmaker Merck filing a lawsuit against Health and Human Services Secretary Xavier Becerra in a federal court, alleging the new policies are “tantamount to extortion.”
The first 10 drugs subject to price negotiations include:
- Eliquis, made by Bristol-Myers Squibb
- Jardiance, made by Boehringer Ingelheim
- Xarelto, made by Johnson & Johnson
- Januvia, made by Merck
- Farxiga, made by AstraZeneca
- Entresto, made by Novartis
- Enbrel, made by Amgen
- Imbruvica, made by AbbVie
- Stelara, made by Janssen
- Fiasp and NovoLog, made by Novo Nordisk
